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Background: Women have a lower risk for coronary artery disease (CAD) and present
at an older age with multiple comorbidities. Young women who present with CAD, albeit
uncommon, likely reflect accelerated progression of atherosclerosis. It is unclear whether
presentation of CAD in women younger than 55 translates into higher rates of target lesion
revascularization (TLR) and target vessel revascularization (TVR) post percutaneous
coronary intervention (PCI). We compared rates of TLR and TVR at 1 year post PCI in
women younger and older than 55.
Methods: 2219 women who underwent PCI at Washington Hospital center for an acute
coronary syndrome were divided by age into four groups (less than 35: 14 patients, 35-45:
83 patients, 45-55: 295 patients, and older than 55: 1827 patients). TLR and TVR were
recorded at 1 year (2030 and 2044 patients respectively).
Results: There were no significant difference in the use of stents, use of drug eluting
stents (DES), stent number, length or diameter in the different age groups. There were no
differences in post PCI care with anti-platelet and statin therapy. Rates of TLR and TVR
were significantly different among the various age groups with higher rates in younger
groups:
Conclusions: Despite comparable rates of stent use, including DES, and comparable post
PCI medical management, women in the younger age groups had higher rates of TLR and
TVR at 1 year post PCI. Coronary artery disease in younger women likely reflects a more
accelerated progression of the disease warranting close follow up.
TCT-370
Outcomes According to Sex Following Unprotected Left Main Stenting With
Drug-Eluting Stents: The Milan Experience
Gill Buchanan1, Alaide Chieffo1, Chiara Bernelli1, Alfonso Ielasi1,
Matteo Montorfano1, Azeem Latib1, Mauro Carlino1, Filippo Figini1,
Irene Franzoni1, Francesco Giannini1, Alessandro Durante1, Santo Ferrarello1,
Alfredo Castelli1, Antonio Colombo1
1San Raffaele Scientific Institute, Milan, Italy
Background: Drug-eluting stents (DES) for the treatment of unprotected left main
coronary artery (ULMCA) disease have been shown to be safe and effective. The aim was
to assess clinical outcomes according to sex in this subset of patients.
Methods: All consecutive patients from our single-center prospective registry treated for
ULMCA stenosis with both first- and new-generation DES from January 2005-June 2010
were analyzed. The study objectives were all-cause mortality, major adverse cardiac
events (MACE), target vessel revascularization (TVR) and target lesion revascularization
(TLR) at 2-years clinical follow-up.
Results: A total of 173 patients were included in the analysis. Notably, only 17.9% were
females. No differences were observed between genders in baseline clinical characteris-
tics. Regarding lesion characteristics, males were more likely to have distal ULMCA
lesions affecting the bifurcation (83.8% vs. 61.3%; p0.005) and undergo a 2-stent
strategy (50.4% vs. 25.8%; p0.013). In addition, males were significantly more likely to
undergo paclitaxel-eluting stent implantation (34.5% vs. 9.7%; p0.006). At 2-years
clinical follow-up, there was a trend for increased all-cause mortality in females (12.9%
vs. 4.2% vs. p0.061). Conversely, there were no significant differences in TLR between
females and males respectively (6.5% vs. 6.3%; p0.981), TVR (22.6% vs. 14.1%;
p0.238), MI (3.2% vs. 1.4%; 0.483), MACE (29.0% vs. 16.9%; p0.119). Moreover,
there were 4 definite/probable stent thrombosis, all in first-generation DES, however this
was not affected by the sex of the patient (3.2% vs. 2.1%; p0.709).
Conclusions: Treatment with DES for ULMCA appears safe and effective regardless of
sex. Despite more distal bifurcation lesions amongst males, there was a trend for a higher
all-cause mortality amongst females which clearly needs to be assessed with larger patient
numbers.
Heart Failure, LV Dysfunction, and Shock
Hall D
Tuesday, October 23, 2012, 8:00 AM–10:00 AM
Abstract nos: 371-391
TCT-371
First Clinical Evaluation of a Novel Percutaneous Right Ventricular Assist
Device: The Impella RP
Anson Cheung1, Darren Freed2, Patrick Hunziker3, Pascal Leprince4
1St Pauls Hospital, Vancouver, British Columbia, 2University of Manitoba,
Winnipeg, Manitoba, 3University Hospital, Basel, Switzerland, 4CHU La Pitié,
Paris, France
Background: Right Ventricular Failure (RVF) is a clinical problem associated with a
high mortality that occurs in a variety of settings including post-cardiotomy cardiogenic
shock, cardiac transplant, right ventricular infarction, pulmonary embolism and after left
ventricular assist device (LVAD) implantation. Temporary mechanical right ventricular
support could be a reasonable alternative treatment option in these patients. We report
here the initial first clinical evaluation of a novel minimally invasive percutaneous right
ventricular assist device.
Methods: Impella RP is a new, minimally invasive, 3D catheter-based percutaneous
microaxial pump that is designed for short-term right ventricular support. The device requires
single vascular access through a sheath in the femoral vein. The device (22 Fr pump mounted
on an 11 Fr catheter) is positioned under fluoroscopic guidance using a 0.025wire. It aspirates
blood from the inferior vena cava and expels it into the pulmonary artery at the maximum rate
of up to 4.4 liters per minute. The device requires low anticoagulation regimen.
Results: A First in Man pre-market clinical feasibility evaluation has been initiated at several
sites in Canada and Europe in patients experiencing right ventricular failure in different clinical
settings.Indications for use at the time of this submission included RVF post heart transplant
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